ClinicalTrials.gg
RecruitingNCT07412132Updated Feb 20, 2026

Evaluation of the Efficacy, Safety, and Tolerability of Lacosamide in Major Depressive Episodes of Bipolar Disorder Types I and II.

A Phase 3 interventional study of Lacosamide and Placebo in Bipolar Affective Disorder, sponsored by University of Sao Paulo. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by University of Sao Paulo · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Bipolar Disorder by University of Sao Paulo — 3 open to participants now, 4 under way, 1 of them phase 3. Bipolar Disorder · University of Sao Paulo.

Planned enrollment
11th of 13
40 · median 60
Started
2026
with 2 others
Phase 3
Only one
of the 15
Registered
14th of 15
by date

Among the 15 studies in Bipolar Disorder by University of Sao Paulo, this one is the 11th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2026, is the only one in phase 3, and was the 14th registered.

Bipolar Disorder

1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

3 of the 15 studies in Bipolar Disorder by University of Sao Paulo are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Bipolar Disorder by University of Sao Paulo, or all of them as a file.
02

Study summary

Initially, observational studies suggested a possible effect of Lacosamide on depressive and anxious symptoms in individuals with epilepsy, and later, an open-label study demonstrated the efficacy of lacosamide in improving depressive and manic symptoms in individuals with bipolar disorder (BD). The primary objective of this study is to evaluate the efficacy of combining lacosamide as an augmentation treatment to first- or second-line medication treatments in moderate to severe major depressive episodes of treatment-resistant BD I and II (failure of at least two adequate treatments during the current episode). The main hypothesis of the study is that lacosamide produces a greater reduction in depression scores compared to a placebo treatment and that both groups will exhibit similar rates of side effects and adverse events. We will conduct a double-blind, randomized, parallel-group pilot study, comparing the enhancement of the treatment that patients had been using with lacosamide and placebo, over a duration of 12 weeks. Forty subjects aged between 18 and 65 years with a diagnosis of BD (I or II) in a moderate or severe major depressive episode, despite the use of first- or second-line treatments, will be selected. The primary outcome will be the assessment of lacosamide efficacy through the difference in scores on the Hamilton Depression Rating Scale (HAMD-17) from the initial visit to the end of week 12 of intervention between the lacosamide and placebo groups.

03

Conditions studied

  • Bipolar Affective Disorder

Browse trials for

Keywords

  • lacosamide
  • randomized clinical trial
  • bipolar disorder
  • bipolar depression
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of bipolar disorder (type I or II) confirmed by structured clinical interview;
  2. acute major depressive episode of moderate or severe intensity;
  3. no response to at least two adequate pharmacological interventions to treat the current episode.

Exclusion criteria

Exclusion Criteria:

  1. Current diagnosis of schizophrenia, dementia, intellectual disability, organic mental disorder (by clinical assessment). Comorbidity with other psychiatric disorders (personality disorders, anxiety disorders, substance use disorders, eating disorders, and attention deficit disorder) will be permitted provided the primary diagnosis is bipolar disorder;
  2. acute suicidal ideation (defined by HAMD-17 item 3 ≥ 3 points or by clinical assessment);
  3. current depressive episode with psychotic features (by clinical assessment);
  4. suspected or confirmed pregnancy;
  5. severe or unstable clinical illnesses;
  6. previous history of non-response to an adequate course of at least 8 sessions of electroconvulsive therapy;
  7. previous history of non-response to an adequate course of ketamine treatment.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Active Group

    Lacosamide 50mg twice a day

    Drug: Lacosamide

  • Placebo comparator
    Placebo Group

    Drug: Placebo

Interventions

  • Lacosamide 50mg will be give twice a day por 2 weeks, then Lacosamide 100mg twice a day until the end of the study.

  • DrugPlacebo

    Placebo tablets are similar in its features to the active drug, but without any pharmacological agent inside.

06

What researchers measure

Primary outcomes

  1. Primary outcome

    The efficacy of lacosamide assessed by the difference in Hamilton Depression Scale score from the initial visit to the end of week 12 of the intervention between the lacosamide and placebo groups. Minimum: 0 point Maximum: 50 points. The increase in the pontuation of the scale is related to worse outcomes.

    Time frame: week 12

Secondary outcomes

  1. Secondary Outcome

    Difference in response rates (50% or more reduction) assessed by the Hamilton Depression Scale from the initial visit to the end of week 12 of intervention, between the lacosamide and placebo groups;

    Time frame: week 12

  2. Secondary outcome

    Difference in response rates (50% or more reduction) assessed by the Montgomery-Asberg Depression Rate Scale from the initial visit to the end of week 12 of intervention, between the lacosamide and placebo groups;

    Time frame: week 12

  3. Secondary outcome

    Difference in remission rates (\< 7 points) assessed by the Hamilton Depression Scale from the initial visit to the end of week 12 of intervention, between the lacosamide and placebo groups;

    Time frame: week 12

  4. Secondary outcome

    Difference in remission rates (\<11 points) assessed by the Montgomery-Asberg Depression Rate Scale from the initial visit to the end of week 12 of intervention, between the lacosamide and placebo groups;

    Time frame: week 12

  5. Secondary outcome

    Difference in side effects from the initial visit to the end of week 12 of intervention, between the lacosamide and placebo groups;

    Time frame: week 12

07

Study locations

1 of 1 sites recruiting
  • Instituto de Psiquiatia (IPQ)
    São Paulo, São Paulo, Brazil
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 12 months after the start.

Of 43 phase 3 interventional studies under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 60. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2026
First posted
Feb 17, 2026
StartActual
Jan 9, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07412132
Collaborators
Libbs Farmacêutica LTDA
Responsible party
Diego Freitas Tavares (Doctorate, University of Sao Paulo) — Principal investigator
First posted
Feb 17, 2026
Start date
Jan 9, 2026
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Feb 20, 2026

Study contacts

Ricardo Alberto Moreno, Professor
Contact
grudaipq@hc.fm.usp.br
+55 11 2661-6648

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lacosamide

Start the discussion